SARS-CoV-2 Spike Glycoprotein S1 

To Order Contact us: stephen@expresspharmapulse.com

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag
E80023
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

Spike S1 RBD, His-tag (SARS-CoV-2)
100687-2 100 µg
EUR 520
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Spike S1 RBD, Fc fusion (SARS-CoV-2)
100699-2 100 µg
EUR 520
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag
E80020
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag
E80022
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag
E80025
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)
100684-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)
100696-2 1 mg
EUR 3200
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike Trimer (S1+S2), His-tag (SARS-CoV-2)
100728-2 1 mg
EUR 2995
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)
100938-2 50 µg
EUR 555
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike Trimer (S1+S2), His-tag (SARS-CoV)
100789-2 500 µg_x000D_
EUR 1900
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike (SARS-CoV-2) Lentivirus
78010-2 500 µl x 2
EUR 2095
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag
E80024-2 1 ml
EUR 4995.1

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion
E80026-2 50 ul
EUR 823.9

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)
100698-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Avi-His-tag (SARS-CoV-2)
100730-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685 with a C-terminal Avi-His-tag, expressed in a HEK293 expression system, MW=78 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)
100769-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)
100846-2 1 mg
EUR 2600
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2)
100992-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. 

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial
E80028-2 100 ul
EUR 860.2

Anti-SARS-CoV-2 Spike S1 Antibody
A3000-50 50 µg
EUR 502.8

Anti-Spike S1 Antibody (SARS-CoV-2)
100715-1 20 µg
EUR 300
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

SARS-CoV-2 (COVID-19) Spike Glycoprotein-S1, Recombinant protein
39-111 0.05 mg
EUR 1520.7
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2)  in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag
E80021-2 1 ml
EUR 4276.8

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag
E80023-2 1 ml
EUR 3934.7

Spike S1 (13-665), Fc Fusion, Avi-tag (SARS-CoV-2)
100678-2 1 mg
EUR 3000
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag, Biotin-labeled (SARS-CoV-2)
100697-2 50 µg
EUR 480
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2)
100719-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, His-Avi-Tag, Biotin-Labeled (SARS-CoV-2)
100937-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This construct contains a C-terminal His-tag (6xHis) followed by an Avi-Tag. The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

Spike S1-Biotin (SARS-CoV-2): ACE2 TR-FRET Assay Kit
79949-2 384 rxns.
EUR 1265
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection._x000D_The SARS-CoV-2 Spike S1:ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 and human ACE2 in a homogeneous 96 or 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, dye-labeled acceptor and an inhibitor for one hour. Then the TR-FRET signal is measured using a fluorescence reader._x000D_ 

Spike S1 (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)
101001-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.7 identified in the United Kingdom and contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6His). The recombinant protein is ≥90% pure following affinity purification.

Spike S1 (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)
101081-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein contains three mutations of interest K417T, E484K and N501Y, in addition to 682RRAR685>A. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified.

Spike S1 (B.1.617.2 Variant) Avi-His-Tag (SARS-CoV-2)
101151-2 1 mg
EUR 2995
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.617.2, also known as variant Delta originally discovered in India, and contains mutations T19R, G142D, R158G, L452R, T478K, D614G and P681R as well as deletion E156-F157. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. 

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag
E80020-2 1 ml
EUR 4276.8

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag
E80022-2 1 ml
EUR 4276.8

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag
E80025-2 1 ml
EUR 3934.7

Spike S1 RBD, Fc-Fusion, Avi-Tag, Biotin-labeled (SARS-CoV-2)
100695-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90% MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)
100731-2 50 µg
EUR 455
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified and enzymatically biotinylated using the Avi-Tag™.

Spike Trimer (S1+S2) (K417T, E484K, N501Y), His- Tag (SARS-CoV-2)
100988-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein contains three mutations: K417T, E484K and N501Y that have been found in emerging SARS-CoV-2 Variants of Concern and may lead to higher transmissibility and infectivity. This mutant Spike Trimer will be useful for structure-function studies, testing of neutralizing antibodies, or antibody and drug screening.  _x000D_The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ?90% pure following affinity purification.

Spike Trimer (S1+S2) (P.1 Variant), His-Tag (SARS-CoV-2)
100989-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 Variant P.1 originally discovered in Brazil and contains 11 mutations in addition to 682RRAR685>A, K986P and V987P, as listed below. The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Spike S1 RBD (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)
100993-2 1 mg
EUR 2995
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to the RBD of SARS-CoV-2 Variant P.1, originally discovered in Brazil, and contains the three mutations  K417T, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following affinity purification.

Spike S1 RBD (B.1.617 Variant), Avi-His-Tag (SARS-CoV-2)
101156-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally identified in India, and contains mutations L452R and E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike Trimer (S1+S2) (B.1.351 Variant), His-Tag (SARS-CoV-2)
510333-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 South African Variant B.1.351 and contains mutations K417N, E484K and N501Y. It also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification._x000D_

Spike Trimer (S1+S2) (B.1.1.7 Variant), His-Tag (SARS-CoV-2)
510334-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 United Kingdom Variant B.1.1.7. It contains mutations N501Y, A570D, D614G, P681H, T716I, S982A, D1118; deletions: 21765:6 (69-70HV), 21991:3 (44Y).  This construct also contains a C-terminal His tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

SARS-CoV-2 (COVID-19) Spike S1 Antibody
9083-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike S1 Antibody
9083-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Spike S1 RBD, His-tag (SARS-CoV-2)
100687-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Spike S1 RBD, Fc fusion (SARS-CoV-2)
100699-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S2, Fc-Tag (SARS-CoV-2)
100895-2 500 µg_x000D_
EUR 1815
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa.

Spike S1 (13-665), Fc fusion, Avi-tag, Biotin-Labeled (SARS-CoV-2)
100679-2 50 µg
EUR 450
Description: Human Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag, Biotin-labeled (SARS-CoV-2)
100720-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 expression system enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=104 kDa. This protein runs at a higher molecular weight due to glycosylation.

Spike S1 (P.1 Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)
101080-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant P.1, also known as variant Gamma originally discovered in Brazil, and contains all ten P.1 mutations, as listed below. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike S1 (K417T, E484K, N501Y), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)
101082-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein contains three mutations of interest K417T, E484K and N501Y (found in the RBD domain of some variants of concern). The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike S1 (B.1.617.1 Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)
101125-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.1, also known as variant Kappa, originally identified in India. It contains mutations G142D, E154K, L452R, E484Q, D614G, and P681R. The construct also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike Trimer (S1+S2) (B.1.617.1, Kappa Variant), His-Tag (SARS-CoV-2)
101144-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.1 also known as variant Kappa originally identified in India, and contains mutations G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (XBB, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101660-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
10-107 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
10-109 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
10-111 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
10-118 0.1 mg
EUR 651.3
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
10-207 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
10-209 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
10-300 0.1 mg
EUR 632.4
Description: SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
21-805 50 ug
EUR 468.6
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein
21-807 50 ug
EUR 437.1
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells.The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) is used as antigen in the Serological ELISA Kit to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma (see SARS-CoV-2 (Spike RBD) IgG Serological ELISA Kit; AG-45B-0020).

SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin)
9083-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin)
9083-biotin-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Recombinant SARS-CoV-2 Spike Protein S1 (His-tag)
P1540-10 10 µg
EUR 211.2

Recombinant SARS-CoV-2 Spike Protein S1 (His-tag)
P1540-50 50 µg
EUR 818.4

Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag)
P1541-10 10 µg
EUR 211.2

Recombinant SARS-CoV-2 Spike Protein S1 (Fc tag)
P1541-50 50 µg
EUR 818.4

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)
100684-1 20 µg
EUR 295
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc fusion (SARS-CoV-2)
100688-1 20 µg
EUR 405
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)
100696-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike Trimer (S1+S2), His-tag (SARS-CoV-2)
100728-1 100 µg
EUR 350
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)
100938-1 20 µg
EUR 420
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)
100938-3 100 µg
EUR 740
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)
79942-2 500 µl x 2
EUR 4405
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
79981-2 500 µl x 2
EUR 5245
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike S1 RBD (V367F), Avi-His-tag Biotin-labeled (SARS-CoV-2) HiP™
100770-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (B.1.617.2, Delta Variant) Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)
101152-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike Trimer (S1+S2) (BA.2.3.20, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101654-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.3.20 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101655-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101656-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant+K444T), His-Tag (SARS-CoV-2)
101657-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 plus mutation K444T. Thus, it contains all the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BN.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101659-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BN.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (XBB.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101661-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.5, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101662-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.5 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BA.4.6, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101664-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.4.6 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BQ.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101665-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BQ.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (BQ.1.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101666-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BQ.1.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike Trimer (S1+S2) (XBB.1.5, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101677-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB.1.5 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-2)
100792 100 µg
EUR 460
Description: Recombinant human monoclonal (clone 414-2) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike Trimer (S1+S2), His-tag (SARS-CoV)
100789-1 100 µg
EUR 450
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

SARS-CoV-2 Spike Peptide
9083P 0.05 mg
EUR 235.5
Description: (NT) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide
9087P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Spike RBD peptide

SARS-CoV-2 Spike Peptide
9091P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide
9095P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

Spike (SARS-CoV-2) Lentivirus
78010-1 100 µl
EUR 835
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)
78028-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (eGFP Reporter)
78035-2 500 µl x 2
EUR 5145
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.

The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag (SARS-CoV-2) HiP™
101153-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 (B.1.1.529 BA.1, Omicron Variant), Avi-His-Tag, (SARS-CoV-2) Recombinant
101333-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.529 BA.1, also known as variant Omicron BA.1 originally identified in South Africa, and contains genetic alterations indicated below. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified.

Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant+V445P+F490S), His-Tag (SARS-CoV-2)
101658-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 plus mutations V445 and F490S. Thus, it contains all the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

SARS-CoV-2 (COVID-19) Biotinylated Spike S1 Recombinant Protein
10-208 0.1 mg
EUR 752.1
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike S1 Recombinant Protein (biotin)
21-806 50 ug
EUR 437.1
Description: SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. The coronaviral genome encodes four major structural proteins: the Spike (S) protein, Nucleocapsid (N) protein, Membrane/Matrix (M) protein and the Envelope (E) protein. The SARS Envelope (E) protein contains a short palindromic transmembrane helical hairpin that seems to deform lipid bilayers, which may explain its role in viral budding and virion envelope morphogenesis. The SARS Membrane/Matrix (M) protein is one of the major structural viral proteins. It is an integral membrane protein involved in the budding of the viral particles and interacts with SARS Spike (S) protein and the Nucleocapsid (N) protein. The N protein contains two domains, both of them bind the virus RNA genome via different mechanisms.The CoV Spike (S) protein assembles as trimer and plays the most important role in viral attachment, fusion and entry. It is composed of a short intracellular tail, a transmembrane anchor and a large ectodomain that consists of a receptor binding S1 subunit (RBD domain) and a membrane-fusing S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) present at the surface of epithelial cells.The SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) is used as antigen in the Serological ELISA Kit to detect anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma (see SARS-CoV-2 (Spike RBD) IgG Serological ELISA Kit; AG-45B-0020).This biotinylated version of SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) forms a tetramer in the presence of streptavidin and this tetramer can be used to activate B cell memory to SARS-CoV-2 Spike protein.

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant
P1531-10 10 µg
EUR 235.2

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant
P1531-50 50 µg
EUR 709.2

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant
P1555-10 10μg
EUR 235.2

Human CellExp™ SARS-CoV-2 Spike Protein (S1), Recombinant
P1555-50 50μg
EUR 709.2

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag
E80024-1 100 ul
EUR 635.8

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion
E80026-1 20 ul
EUR 588.5

Recombinant SARS-CoV-2 Spike S1 Protein with His-Tag
E80004-1 100 ul
EUR 518.1

Recombinant SARS-CoV-2 Spike S1 Protein with His-Tag
E80007-1 100 ul
EUR 518.1

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)
100698-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Avi-His-tag (SARS-CoV-2)
100730-1 100 µg
EUR 320
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685 with a C-terminal Avi-His-tag, expressed in a HEK293 expression system, MW=78 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)
100769-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1)
100793 100 µg
EUR 485
Description: Recombinant human monoclonal (clone 414-1) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike Trimer (S1+S2) (D614G), His-tag (SARS-CoV-2)
100810 100 µg
EUR 450
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682-685>A, K986P, V987P, and D614G mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=137 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)
100846-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (G476S), Avi-His-tag (SARS-CoV-2)
100868 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with G476S mutation and with a C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2)
100992-1 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. 

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag
E80027
  • EUR 635.80
  • EUR 4087.60
  • 1 ml
  • 100 ul

SARS-CoV Spike Antibody
3219-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3219-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3221-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3221-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3223-002mg 0.02 mg
EUR 206.18
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3223-01mg 0.1 mg
EUR 523.7
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3225-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3225-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Protein
abx060655-1mg 1 mg
EUR 2030.4

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial
E80028-1 20 ul
EUR 388.3

Spike S1 (B.1.1.529 BA.1, Omicron Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2)
101334-2 100 µg
EUR 665
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.529 BA.1, also known as variant Omicron BA.1 originally identified in South Africa, and contains genetic alterations indicated below. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis).  The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

Recombinant Coronavirus Spike Protein (SARS-CoV S1; His tag)
P1516-10 10µg
EUR 308.4

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)
78614-2 500 µl x 2
EUR 4320
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)
78112-2 500 µl x 2
EUR 4405
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)
78637-2 500 µl x 2
EUR 3995
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices.

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)
79982-2 500 µl x 2
EUR 8110
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_
The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_

3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate
79952-2 10 mg
EUR 3460
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹.

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S1), Recombinant
P1524-10 10 µg
EUR 332.4

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag
E80021-1 100 ul
EUR 635.8

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag
E80023-1 100 ul
EUR 635.8

Spike S1 (13-665), Fc Fusion, Avi-tag (SARS-CoV-2)
100678-1 100 µg
EUR 350
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag, Biotin-labeled (SARS-CoV-2)
100697-1 25 µg
EUR 325
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2)
100719-1 100 µg
EUR 320
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike Trimer (S1+S2), His-tag, Eu-labeled (SARS-CoV-2)
100894 25 µg
EUR 295
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), Genbank Accession No. MN908947, a.a. 16-1213, with a with C-terminal His-tag, Eu-labeled, expressed in a HEK293 expression system. MW=139 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1, Avi-His-Tag, iFluor-488-labeled (SARS-CoV-2)
100936 10 µg
EUR 320
Description: iFluor-488-labeled SARS-CoV-2 Spike S1 (a.a. 16-685, with C-terminal Avi-His-Tag. MW = 78 kDa + glycans

Spike S1 RBD, His-Avi-Tag, Biotin-Labeled (SARS-CoV-2)
100937-1 20 µg
EUR 295
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This construct contains a C-terminal His-tag (6xHis) followed by an Avi-Tag. The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

Spike S1 RBD (SARS-CoV-2): ACE2 Inhibitor Screening Assay Kit
79931 96 rxns.
EUR 675
Description: The SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of bound His-labeled ACE2 by HRP-labeled Anti-His. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike is coated on a 96-well plate. Next, ACE2-His is incubated with SARS-CoV-2 Spike on the plate. Finally, the plate is treated with Anti-His-HRP followed by addition of an HRP substrate to produce chemiluminescence, which then can be measured using a chemiluminescence reader.

ACE2: Spike S1 RBD (SARS-CoV-2) Inhibitor Screening Assay Kit
79936 96 rxns.
EUR 660
Description: The ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of bound Fc-tagged Spike protein by HRP-labeled Anti-Fc. Only a few simple steps on a microtiter plate are required for the assay. First, ACE2 protein is attached to a nickel-coated 96-well plate. Next, SARS-CoV-2 Spike-Fc is incubated with ACE2 on the plate. Finally, the plate is treated with Anti-Fc-HRP followed by addition of an HRP substrate to produce chemiluminescence, which then can be measured using a chemiluminescence reader.

ACE2: Spike S1-Biotin (SARS-CoV-2 ) Inhibitor Screening Assay Kit
79945 96 rxns.
EUR 865
Description: Coronavirus disease 2019 (COVID-19) increases the risk of developing Acute Respiratory Distress Syndrome (ARDS), which is often fatal at the late stages of the infection when the SAR-CoV-2 virus causes significant damage to the lungs. As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike S1 protein recognizes and attaches to the Angiotensin Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike S1 protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection.

The ACE2:SARS-CoV-2 Spike S1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of Spike S1-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, ACE2 protein is attached to a nickel-coated 96-well plate. Next, SARS-CoV-2 Spike S1-Biotin is incubated with ACE2 on the plate. Finally, the plate is treated with Streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which then can be measured using a chemiluminescence reader.

Spike S1-Biotin (SARS-CoV-2): ACE2 TR-FRET Assay Kit
79949-1 96 rxns.
EUR 905
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection._x000D_The SARS-CoV-2 Spike S1:ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 and human ACE2 in a homogeneous 96 or 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, dye-labeled acceptor and an inhibitor for one hour. Then the TR-FRET signal is measured using a fluorescence reader._x000D_ 

Spike S1 (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit
79954 96 rxns.
EUR 845
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection_x000D_The SARS-CoV-2 Spike S1:ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike S1 protein is attached to a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike S1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce color, which can then be measured using a UV/Vis spectrophotometer microplate reader.

Spike S1 (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)
101001-1 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.7 identified in the United Kingdom and contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6His). The recombinant protein is ≥90% pure following affinity purification.

Spike S1 (P.1 Variant), Avi-His-Tag (SARS-CoV-2)
101079 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 Variant P.1, also known as variant Gamma, originally discovered in Brazil and contains all P.1 mutations in addition to 682RRAR685>A, as listed below. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified.

Spike S1 (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)
101081-1 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein contains three mutations of interest K417T, E484K and N501Y, in addition to 682RRAR685>A. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified.

Spike S1 (B.1.618 Variant), Avi-His-Tag (SARS-CoV-2)
101126 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.618 originally identified in India, and contains deletions Y145 and H146 as well as mutations E484K and D614G. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified.

Spike S1 (B.1.429 Variant), Avi-His-Tag (SARS-CoV-2)
101130 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.429, also known as variant Epsilon originally discovered in California (USA), and contains mutations W152C, L452R and D614G. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Spike S1 (B.1.617.2 Variant) Avi-His-Tag (SARS-CoV-2)
101151-1 100 µg
EUR 335
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.617.2, also known as variant Delta originally discovered in India, and contains mutations T19R, G142D, R158G, L452R, T478K, D614G and P681R as well as deletion E156-F157. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. 

SARS-CoV-2 Spike S2 Peptide
9119P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike S2 Peptide
9123P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Monoclonal Antibody
A73664-050 50 ul
EUR 341

SARS-CoV-2 Spike Monoclonal Antibody
A73664-100 100 ul
EUR 518.1

SARS-CoV-2 Spike RBD Nanobody
A73680-050 50 ul Ask for price

SARS-CoV-2 Spike RBD Nanobody
A73680-100 100 ul
EUR 882.2

SARS-CoV-2 Spike Monoclonal Antibody
A73664
  • EUR 341.00
  • EUR 518.10
  • 50 ul
  • 100 ul

SARS-CoV-2 Spike RBD Nanobody
A73680
  • Ask for price
  • EUR 882.20
  • 50 ul
  • 100 ul

Spike S1 RBD (B.1.1.7; Alpha Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™
100999-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, also known as variant Alpha originally identified in the United Kingdom, and contains mutation N501Y. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™
101154-2 50 µg
EUR 455
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 (B.1.617.2.1, Delta Plus Variant) Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™
101180-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R as well as deletion E156/F157. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV-1), Biotin-labeled
100785-2 100 µg
EUR 595
Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids.

Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78625-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K

Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
78626-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1 (B.1.1.529), BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 BA.2 Variant Spike (Genbank Accession #QHD43416.1 containing all the BA.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2 Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K

Spike RBD (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)
100977-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, originally discovered in the United Kingdom, and contains mutation N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Spike RBD (B.1.351 Variant) Avi-His-Tag (SARS-CoV-2)
100978-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.351, orignally discovered in South Africa and contains mutations K417N, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification and shows less than 5% aggregation in gel filtration. 

Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78142-2 500 µl x 2
EUR 4320
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_

Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78143-2 500 µl x 2
EUR 4195
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_

Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78144-2 500 µl x 2
EUR 4195
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_

Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
78158-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. The United Kingdom (UK) identified a variant called B.1.1.7 with a large number of mutations in the fall of 2020. This variant spreads more easily and quickly than other variants.
The Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.7 variant Spike (Genbank Accession #QHD43416.1 with B.1.1.7 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP fluorescence. The Spike (B.1.1.7 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.7 variant in a Biosafety Level 2 facility.

Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
78159-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection.
In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with P.1 mutations, see below for details) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility.

Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
78160-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection.
A variant called B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This South African variant, also known as 501Y.V2, has many mutations that may lead to higher transmissibility and infectivity. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (B.1.351) variant in a Biosafety Level 2 facility.

Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)
78642-2 500 µl x 2
EUR 3995
Description: The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 D614G variant in a Biosafety Level 2 facility.The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells.

SARS-CoV-2 (COVID-19) Spike Glycoprotein-S2, Recombinant protein
39-112 0.05 mg
EUR 1520.7
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2)  in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.

Spike S1 RBD (B.1.617.2.1, Delta Plus Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™
101182-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains RBD mutations K417N, L452R and T478K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike Trimer (S1+S2) (BF.7/BA.5.2.6/BF.11, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant
101663-2 100 µg
EUR 625
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BF.7/BA.5.2.6/BF.11 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified.

SARS-CoV spike protein Antibody
abx023139-100ug 100 ug
EUR 1028.4

SARS-CoV spike protein Antibody
abx023143-100ug 100 ug
EUR 1028.4

Anti-CoV-2 & SARS-CoV S1 Antibody (Clone# CR3022)
A2103-200 200 µg
EUR 576

3CL Protease (SARS-CoV-2)
100823-2 500 µg_x000D_
EUR 3360
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa.

Human CellExp™ SARS-CoV-2 Spike Protein (S1; His-tag), Recombinant
P1532-10 10 µg
EUR 187.2

Human CellExp™ SARS-CoV-2 Spike Protein (S1; His-tag), Recombinant
P1532-50 50 µg
EUR 661.2

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag
E80020-1 100 ul
EUR 635.8

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag
E80022-1 100 ul
EUR 635.8

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag
E80025-1 100 ul
EUR 635.8

Recombinant SARS-CoV-2 Spike S1 Protein with hFc and His-Tag
E80001-1 100 ul
EUR 518.1

SARS-CoV-2 Spike Glycoprotein S1